Generali Investments CEE investicni spolecnost a.s. Buys Shares of 5,108 Solventum Co. (NYSE:SOLV)

Generali Investments CEE investicni spolecnost a.s. acquired a new position in shares of Solventum Co. (NYSE:SOLV - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 5,108 shares of the company's stock, valued at approximately $337,000.

Other hedge funds also recently modified their holdings of the company. Hotchkis & Wiley Capital Management LLC bought a new stake in Solventum during the third quarter worth $125,488,000. Trian Fund Management L.P. raised its holdings in shares of Solventum by 32.9% in the 3rd quarter. Trian Fund Management L.P. now owns 7,126,255 shares of the company's stock valued at $496,842,000 after purchasing an additional 1,765,676 shares during the period. Point72 Asset Management L.P. acquired a new stake in Solventum in the 3rd quarter valued at about $50,948,000. Nordea Investment Management AB increased its position in Solventum by 189.5% during the fourth quarter. Nordea Investment Management AB now owns 659,887 shares of the company's stock worth $43,902,000 after buying an additional 431,986 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Solventum during the fourth quarter worth approximately $18,583,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on SOLV shares. Bank of America increased their price target on Solventum from $80.00 to $85.00 and gave the company a "neutral" rating in a research note on Wednesday, February 26th. Morgan Stanley raised their target price on shares of Solventum from $73.00 to $80.00 and gave the stock an "equal weight" rating in a research note on Wednesday, March 5th. The Goldman Sachs Group upped their price target on shares of Solventum from $63.00 to $71.00 and gave the company a "sell" rating in a research note on Monday, March 3rd. Wells Fargo & Company raised their price objective on shares of Solventum from $73.00 to $75.00 and gave the stock an "equal weight" rating in a research report on Friday, February 28th. Finally, Piper Sandler boosted their price objective on Solventum from $75.00 to $84.00 and gave the stock a "neutral" rating in a report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $79.86.

Remove Ads

Solventum Price Performance

SOLV stock traded down $1.57 during midday trading on Thursday, reaching $72.44. The company had a trading volume of 876,049 shares, compared to its average volume of 1,436,098. Solventum Co. has a 1-year low of $47.16 and a 1-year high of $85.92. The stock has a 50 day moving average price of $74.24 and a 200-day moving average price of $70.96. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The company has a market capitalization of $12.53 billion and a price-to-earnings ratio of 26.34.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.